ArticleMedical oncology (Northwood, London, England)2025
Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Lactate metabolism regulation enhances cuproptosis to activate antitumor immunity: Synergistic therapy of hyaluronic acid nanomicelles delivering lactate oxidase/copper-doped carbon dots combined with α-PD-L1 inhibits distant tumors.Materials today. Bio · 2026Article
- Metformin potentiates DSF/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer.BMC biotechnology · 2026Article
- Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy.Medical oncology (Northwood, London, England) · 2025Article
- Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells.Scientific reports · 2025Article
- Curcumin and Silibinin loaded pegylated nanoniosome for cancer therapy: bioinformatics and in vitro study.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on developing a novel nanoformulation involving hyaluronic acid (HA) coated niosomes (NIOs) containing Fingolimod (FTY720) and quantum dots (QDs) for targeted therapy and metastasis inhibition of triple-negative breast cancer (TNBC). HNio@QDFTY720 NPs were synthesized via thin film hydration method (TFH), resulting in a size of 126.4 nm, a polydispersity index (PDI) of 0.476, and a zeta potential of - 17.6 mV. The encapsulation efficiency was determined to be 98.5%, with drug release studies revealing a pH-sensitive release profile approximately 50% release at pH 7.4, compared to 87.32% at pH 5.8, within 72 h. Cellular uptake studies demonstrated that HNio@QD NPs significantly enhanced drug localization in CD44 + MDA-MB-231 cells. MTT assay indicated that Nio@FTY720 exhibited greater cytotoxicity than the free drug, with HNio@QDFTY720 showing the highest efficacy across all tested concentrations. Annexin V-FITC/PI analysis confirmed induction of massive apoptosis and necrotic cell death, and complete inhibition of cell migration by wound healing assay achieved by HNio@QDFTY720 compared to free drug and control. Bioinformatics study confirmed that majority of Fingolimod target genes were enriched in cell motility, migration and movement and were highly correlated with survival status of breast cancer patients. These findings suggest that niosomal formulation of FTY720 significantly enhances cytotoxic effects against TNBC and represent a promising strategy for improving therapeutic outcomes in metastatic TNBC through targeted drug delivery.
Indexed as
Identifiers
40506644What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.